cl 3 saenger martin

55
Clinical Track: Improved Outcomes with Improved Prescribing Prac<ces Presenters: Michael Saenger, MD, FACP Robert E Mar<n, J.D.,CEAP Moderator: Dr. David Sugerman, MD, MPH, FACEP, CDR

Upload: opunite

Post on 21-Jan-2015

167 views

Category:

Business


1 download

DESCRIPTION

 

TRANSCRIPT

Page 1: Cl 3 saenger martin

Clinical  Track:    Improved  Outcomes  with  

Improved  Prescribing  Prac<ces    

Presenters:  Michael  Saenger,  MD,  FACP  Robert  E  Mar<n,  J.D.,CEAP  

Moderator:  Dr.  David  Sugerman,  MD,  MPH,  FACEP,  CDR    

Page 2: Cl 3 saenger martin

Disclosures  

•  Michael  Saenger  has  disclosed  no  relevant,  real  or  apparent  personal  or  professional  financial  rela<onships.  

•  Robert  E  Mar<n  has  disclosed  no  relevant,  real  or  apparent  personal  or  professional  financial  rela<onships.  

Page 3: Cl 3 saenger martin

Learning  Objec<ves  

1.  Outline  strategies  for  incorpora<ng  improved  prescribing  methods  into  a  physician’s  prac<ce.    

2.  Assess  chronic  pain  pa<ents  for  their  probability  to  abuse  opiates.    

3.  Iden<fy  alterna<ve  methods  of  trea<ng  chronic  pain  pa<ents  who  abuse  opiates.    

Page 4: Cl 3 saenger martin

Improved  Outcomes  with  Improved  Prescribing  Prac<ces  

Michael  Saenger,  MD,  FACP  Pain  Management  Lead  Physician,  VISN  7  

Director,  Empower  Veterans;  Atlanta  VA  Medical  Center  April  22,  2014  

Na<onal  Rx  Drug  Abuse  Summit  

Page 5: Cl 3 saenger martin

Overview  

•  Background  of    – Chronic  Pain  – VA  Models  – Evidence  for  Opioids  in  Chronic  Pain  

•  Examples  of  Improvement  – Grady  Health  System’s  Primary  Care  – Atlanta  VA  Medical  Center  Community  Clinic  – Minneapolis  VA  – VHA  Opioid  Safety  Ini<a<ve  

Page 6: Cl 3 saenger martin

Complex  Chronic  Pain:    Dis<nct  from  Acute  Nocicep<ve  Pain  

Mariano  et  al;  VISN  20  and  7  Bio-­‐Psycho-­‐Social  Training;  2014  

Page 7: Cl 3 saenger martin

Recent  Veterans  and  Chronic  Pain:    50%  OEF  Men;  75%  OEF  Women  

Lew,…  Kerns,  Clark  and  Cifu;  JRRD;  2009  

PTSD

Chronic Pain

mTBI

Page 8: Cl 3 saenger martin

VHA  Stepped  Care  Model    for  Chronic  Pain  Management  

Step  3  MulB-­‐  

Disciplinary  

Step  2  Subspecialty  Consults  

Step  1  PACT  –Veteran  (Self  Care  desired)  

PACT  =  Pa<ent  Aligned  Care  Team,    Aka  Pa<ent  Centered  Medical  Home  

Page 9: Cl 3 saenger martin

From  VHA    The  Office  of    

Pa<ent  Centered  Care  and  Cultural  

Transforma<on  

Personalized  Health    Plan  

Page 10: Cl 3 saenger martin

No  Change  in  Chronic  Low  Back  Pain  73mg  Morphine  versus  Placebo  

Martell  …  Kerns…;  Ann  Int  Med;  2007  

Page 11: Cl 3 saenger martin

Cyber  Seminar,  2012  

Risk  VA  Overdose  Death  by  Dose  

Page 12: Cl 3 saenger martin

Improvements  –  Primary  Care  Grady  Health  System  

•  Con<nuity  clinic  –  2  coun<es  – Safety-­‐net  facility    – Resident  clinics    – Pa<ents  from  served  AND  distant  coun<es    

•  Task  Force  –  Inter-­‐professional,  mul<-­‐disciplinary  – New  Policy;  Medica<on  Agreement  and  Log  Book  

Page 13: Cl 3 saenger martin

Improvements  –  Primary  Care  Grady  Health  System  

•  Nurse  sustained    – Medica<on  Agreement  

– Urine  Drug  Screening  

•  30%  reduc<on  in  monthly  opioid  prescrip<ons  

Page 14: Cl 3 saenger martin

Improvements  –    Community  Based  Outpa<ent  Clinic  

Atlanta  VA  Medical  Center  

•  Inter-­‐professional  Re-­‐educa<on  

•  System  and  Quality  Improvement  approach  – How  to  accomplish  efficiently?  

•  eConsulta<on  

Page 15: Cl 3 saenger martin

Re-­‐Learning,  Inter-­‐Professionally  

Really ALL PCMH: Clerk, LPN, Social Worker, Clinical Pharmacist, Dietician, Psychologist…

Page 16: Cl 3 saenger martin

AND  in  ALL  Sub-­‐Specialty  Clinics…  

•  Emergency  Department  •  Dental  •  Orthopedics,  General  and  Neuro  Surgery  …  •  Gynecology  •  Neurology,  Hematology  &  Inpa<ent  Medicine  

•  Pain  Clinic  and/or  PM&R  

•  Mental  Health  

Page 17: Cl 3 saenger martin

“Universal  Precau<ons”  

•  Counseling  and  Expecta<on  Agreement  •  One  prescriber  •  Regular  appointments  

•  Func<onal  re-­‐assessment  

•  Par<cipate  in  mul<-­‐modal  plan  

•  Frequent  Urine  Drug  Screening  (UDS)  •  Prescrip<on  Drug  Monitoring  Program  (PDMP)  

Page 18: Cl 3 saenger martin

Improvements  –    Community  Based  Outpa<ent  Clinic  

Atlanta  VA  Medical  Center  

Page 19: Cl 3 saenger martin

Opioid  Safety  Ini<a<ve  (OSI)  

•  VHA  Central  Office    – Co-­‐Led  by  Dr.  Kerns,  recent  Director  Pain  for  VA  

•  Goal:  safety  by  reducing  high  dose  opioids  

•  ID:  top  prescribers  for  every  facility  

•  Re-­‐emphasizing:  “3  Step  Model”  of  pain  care  

Page 20: Cl 3 saenger martin

OSI  Goals  <  6  Months,  updated:  April  2,  2014  Dr.  Petzel,  Under-­‐Secretary  for  Health  for  VA  

1.  Educate  for  safe  and  effec<ve  use  of  UDS:                    All  prescribers  of  opioids  

2.  Increase  use  of  UDS  

3.  Educate  prescribers  to  use  state’s  PDMP  

4.  Establish  safe  and  effec<ve  tapering  program:  Star<ng  with  Benzodiazepine  +  Opioid  group  

Page 21: Cl 3 saenger martin

OSI  Goals  <  9  Months,  updated:  April  2,  2014  Dr.  Petzel,  Under-­‐Secretary  for  Health  for  VA  

5.    Field  Risk  Stra<fica<on  Toolkit,  for  those  who:    Should  not  be  on  LTOT;  or    Should  be  on  less  LTOT  

6.  Establish  systems  of  care  for  tapering:    Methadone    Oxycodone    Hydromorphone  

Page 22: Cl 3 saenger martin

OSI  Goals  <  12  Months,  updated:  April  2,  2014  Dr.  Petzel,  Under-­‐Secretary  for  Health  for  VA  

7.  Review  all  pa<ents  on  >  200  mg  MEDD  

8.  Provide  at  least  two  approved  Complementary  and  Alterna<ve  therapies  (CAM)  at  each  Facility  

9.  Explore  use  of  Behavioral  Health  Interdisciplinary  Program  Model  in  Conjunc<on  with  Pa<ent  Aligned  Care  Team  

Page 23: Cl 3 saenger martin

Improvements  -­‐  Minneapolis  VA  

•  Leter  from  Chief  of  Staff  to  Providers  

•  2  hour  Opioid  Safety  Ini<a<ve  Educa<on  

•  Q2Month  Audit  and  Feedback  on  %  on  either    – Oxycon<n  –  >  200  mg  MED  

•  Chronic  Pain  eConsult  Service  

Page 24: Cl 3 saenger martin
Page 25: Cl 3 saenger martin

0  

200  

400  

600  

800  

1000  

1200  

Dec'10  

Jan'11

 Feb'11

 Mar'11  

Apr'11  

May'11  

Jun'11

 Jul'11  

Aug'11  

Sep'11  

Oct'11  

Nov'11  

Dec'11  

Jan'12

 Feb'12

 Mar'12  

Apr'12  

May'12  

Jun'12

 Jul'12  

Aug'12  

Sep'12  

Oct'12  

Nov'12  

Dec'12  

Jan'13

 Feb'13

 Mar'13  

Apr'13  

May'13  

Jun'13

 Jul'13  

Aug'13  

Sep'13  

Fentanyl  Patch  

Methadone  

Morphine    

Oxycodone  IR    

Oxycodone/APAP    

OxyConBn  

Minneapolis  VA    Opioid  PrescripBon  Trends  December  2010  –  September  2013  

Anders  Westanmo,  PharmD  and  Peter  Marshall,  MD  

Page 26: Cl 3 saenger martin

Improvements  -­‐  VHA  with  OSI  

•  Key  indicators  progress  July  2012  -­‐  Dec  2013:  – 27,783  more  Veterans  on  long-­‐term  opioids  had  an  urine  drug  screen  

– 13,859  fewer  Veterans  on  long-­‐term  opioids  

– 10,664  fewer  Veterans  on  opioids  and  benzodiazepines  at  the  same  <me  

– Average  dose  per  day  of  select  opioids  has  begun  to  decline  slightly  

Page 27: Cl 3 saenger martin

VISN  7  “Supplemental  Guidelines”  to  2010  VA-­‐DoD  Clinical  Prac<ce  Guidelines  

•  Right  Pa<ent  [Contra-­‐Indica<ons]  

•  “Universal  Precau<ons”  Bundle  [Safety]  

•  Ceiling  Dosages  [for  Opioid  Trial]  

Page 28: Cl 3 saenger martin

VISN  7  [Contra-­‐indica<ons]:  Phased-­‐In  

Page 29: Cl 3 saenger martin

VISN  7  Ceiling  Dosages:  Phased-­‐In  

•  <  100  mg  MED  (Morphine  Equivalents  Daily)  – No  Contra-­‐indica<ons  

•  <45mg  MED  – Rela<ve  Contra-­‐indica<ons  

•  0  mg  – Absolute  Contra-­‐indica<ons  

Page 30: Cl 3 saenger martin

VISN  20…  Web-­‐Based  Training  Modeling  Bio-­‐Psycho-­‐Social  Approach  

Page 31: Cl 3 saenger martin

Collabora<ve  Self-­‐Care  

•  Bio-­‐Psycho-­‐Social-­‐Spiritual  Approach      

–  Involving  all  of  Pa<ent  Centered  Medical  Home  

– Caring  for  whole  person    

Kerns,  Mariano,  Hunt,  Burgo  and  many  others  

Page 32: Cl 3 saenger martin

Focusing  on  Func<on  

•  Not  on  “5th  Vital  Sign”  

•  Applying  Mo<va<onal  Interviewing    

•  Coaching  all  Veterans  to  prac<ce:  – Stress  Management  – Gradual,  progressive  exercise  

Kerns,  Mariano,  Hunt,  Burgo  and  many  others  

Page 33: Cl 3 saenger martin

Addressing  pain  aggravators  

•  Undertreated  Mental  Health  concerns  (PTSD/Anxiety…)  

•  Moral  Injury  

•  Central  Sensi<za<on  Syndromes  

•  Substance  Abuse  

Page 34: Cl 3 saenger martin

Proven  Help  =  CBT  Cogni<ve  Behavioral  Therapy  

•  Training  for  ALL  with  Chronic  Pain:  

– Relaxa<on  and  Mindful  Acceptance  

– Overcoming  Catastrophizing  and  Fear  of  Pain  •  “Mo<on  is  Lo<on”  

– Goals  and  Pacing  •  Progressive  small  improvements  

Page 35: Cl 3 saenger martin

Adjunc<ve  Therapies  •  Complementary  /  Integra<ve  Medicine  (CAM)  

–  Alexander  technique  or  Yoga  or  Mindfulness;  and  –  Massage  or  Spinal  Manipula<on  or  Acupuncture  

•  Non-­‐opioid  Analgesics  

•  ?  S<mulators  

•  Most  do  not  need    –  Opioids  round  the  clock  –  Injec<ons  nor  Surgeries  –  Step  3,  Mul<disciplinary  Pain  Clinic  

Saenger,  APA  PCSS-­‐O  Webinars,  Evidence  for  CAM  for  Chronic  LBP,  parts  1&2,  2013  

Page 36: Cl 3 saenger martin

Summary:  Need  System  of  Changes  •  BETTER  Pain  Management  Strategies  for  our  Pa<ents  

–  Integrated  self-­‐management  training                                                                                                                (behavioral  &  movement  therapies)  

•  Supplemental  Guidance  –  supported  by  –  Leadership  –  Stakeholders  

•  Educa<on  –  Inter-­‐professional  

•  Audit  and  Feedback  

•  Support  for  Primary  Care  –  Efficiencies  –  Sub-­‐Specialty  eConsulta<on  ….  

Page 37: Cl 3 saenger martin

Ques<ons?  

Page 38: Cl 3 saenger martin

Improved  Outcomes  With  Improved  Prescribing  Prac<ces  

Robert  E  Mar<n,  J.D.,CEAP  Director  of  Substance  Abuse  Services  

Carolinas  Healthcare  System  

Page 39: Cl 3 saenger martin

Objec<ves  

1.  Discuss  strategies  for  incorpora<ng  improved  prescribing  methods  into  a  physician’s  prac<ce.  

2.  Assess  chronic  pain  pa<ents  for  their  probability  to  abuse  opiates.  

3.  Iden<fy  alterna<ve  methods  of  trea<ng  chronic  pain  pa<ents  who  abuse  opiates.  

Page 40: Cl 3 saenger martin

Collateral  Damage  

•  Drug  overdose  was  the  leading  cause  of  injury  death  in  2010.  Among  people  25  to  64  years  old,  drug  overdose  caused  more  deaths  than  motor  vehicle  traffic  crashes.  

•  Drug  overdose  death  rates  have  been  rising  steadily  since  1992  with  a  102%  increase  from  1999  to  2010  alone.  

                                                                                           www.cdc.gov  

Page 41: Cl 3 saenger martin

Where  Do  All  The  Opiates  Come  From?  

Page 42: Cl 3 saenger martin

Where  Do  The  Opiates  Go?  

•  In  2010,  of  the  38,329  drug  overdose  deaths  in  the  United  States,  22,134  (60%)  were  related  to  pharmaceu<cals.  

•  Of  the  22,134  deaths  rela<ng  to  prescrip<on  drug  overdose  in  2010,  16,651  (75%)  involved  opioid  analgesics  (also  called  opioid  pain  relievers  or  prescrip<on  painkillers)  

•  In  2011,  about  1.4  million  ED  visits  involved  the  nonmedical  use  of  pharmaceu<cals.  Among  those  ED  visits,  501,207  visits  were  related  to  an<-­‐anxiety  and  insomnia  medica<ons,  and  420,040  visits  were  related  to  opioid  analgesics.  

                                                                                                                                             www.cdc.gov  

Page 43: Cl 3 saenger martin

Risk  Factors  •  Family  history  of  addicBon.  Drug  addic<on  is  more  common  in  some  families  and  likely  involves  the  effects  of  many  genes.    

•  Being  male.  Men  are  twice  as  likely  to  have  problems  with  drugs.  New  flash!  This  is  changing.  

•  Having  another  psychological  problem.    •  Peer  pressure.  Par<cularly  for  young  people,  peer  pressure  is  a  strong  factor  in  star<ng  to  use  and  abuse  drugs.    

•  Lack  of  family  involvement.    •  Anxiety,  depression  and  loneliness.  Using  drugs  can  become  a  way  of  coping  with  these  painful  psychological  feelings.    

•  Taking  a  highly  addicBve  drug.    

Page 44: Cl 3 saenger martin

What  is  it?  

•  Addic<on  

•  Pseudo-­‐addic<on  (inadequate  analgesic)  

•  Other  psychiatric  diagnoses:  encephalopathy,  borderline  personality  disorder,  depression,  and  anxiety  

•  Criminal  intent    

Page 45: Cl 3 saenger martin

Managing  the  Risk  •  Treatment  agreements  

•  One  physician  •  One  pharmacy  

•  Appointments  

•  Prescrip<on  frequency  •  Include  family  or  important  persons  

•  Non-­‐adherence  •  Urine  drug  screens  

•  Specific  substance  iden<fica<on  •  So  the  failed  now  what?  

Page 46: Cl 3 saenger martin

Partnering  

•  Refer  for  assessment  •  Selec<ng  a  program  

•  Con<nuing  case  management  

•  Are  you  undertrea<ng  the  pain?  •  Has  tolerance  increased/ineffec<ve  medica<on/dosing  

•  Refer  for  assessment  

Page 47: Cl 3 saenger martin

Which  Pa<ent  Do  You  See?  •  Not  out  of  control  •  Quality  of  life    •  Would  decrease  

medica<ons  if  side    effects  are  present  

•  Treatment  plan  to  address  physical  problem  and  ac<ve  in  using  other  forms  of  treatment  

•  Follows  the  agreement  for  the  use  of  opioids    

•  May  have  medica<on  le{  over  or  request  for  refills  are  consistent  with  schedule.  

•  Wants  more  and  more  o{en  

•  Pain  medica<on  has  decreased  quality  of  life    

•  Opiates  despite  side  effects  

•  Unaware  or  in  denial  about  problems  and  singularly  focused  on  drug  therapy  

•  Violates  medica<on  contract  

•  “The  dog  ate  my  homework”  

Page 48: Cl 3 saenger martin

What  Do  They  Do  With  The  Prescrip<ons?  

•  Sell  

•  Trade  

• Horde  

• Use  

Page 49: Cl 3 saenger martin

Why  do  paBents  turn  to  heroin?  

•  Cheaper  •  Works  •  PaBent  in  control  of  medicaBon  •  Physician  did  not  assess  

addicBon  potenBal  

Page 50: Cl 3 saenger martin

White  powder  heroin  “China  White”  

Page 51: Cl 3 saenger martin

Heroin  

•  Black  Tar  Heroin    

Page 52: Cl 3 saenger martin

Black  Tar  Heroin  

•  Rela<vely  crude  and  unrefined  opiate  product,  does  not  require  the  complex  lab  equipment,  high-­‐purity  acetyla<ng  chemicals  or  lengthy  steps  necessary  to  produce  pure  heroin.    

•  Atrac<ve  to  clandes<ne  drug  producers.  •  Black  tar  heroin  is  produced  in  La<n  America.  •  Most  commonly  found  in  the  western  and  southern  parts  of  the  United  States.  

•  Best  zip  codes  of  Charlote.  •  Younger  people  and  professionals.    

Page 53: Cl 3 saenger martin

Non-­‐opiate  Treatments  

•  Massage  •  Hydro  •  Acupuncture  •  Guided  imagery  •  Non-­‐opiate  medica<ons  •  Electro  s<mula<on  •  Physical  therapy  •  Not  every  injury  is  reversible  

Page 54: Cl 3 saenger martin

What  Now?  

Page 55: Cl 3 saenger martin

Thank  You.  Now  Some  Ques<ons    For  More  Informa<on…….